Reciprocal regulation of extracellular signal regulated kinase 1/2 and mitogen activated protein kinase phosphatase-3.
Mitogen activated protein kinase phosphatase-3 (MKP-3) is a putative tumor suppressor. When transiently overexpressed, MKP-3 dephosphorylates and inactivates extracellular signal regulated kinase (ERK) 1/2. Little is known about the roles of endogenous MKP-3, however. We previously showed that MKP-3 is upregulated in cell lines that express oncogenic Ras. Here we tested the roles of endogenous MKP-3 in modulating ERK1/2 under conditions of chronic stimulation of the Ras/Raf/MEK1/2/ERK1/2 pathway by expression of oncogenic Ras. We used two cell lines: H-ras MCF10A, breast epithelial cells engineered to express H-Ras, and DLD-1, colon cancer cells that express endogenous Ki-Ras. First, we found that MKP-3 acts in a negative feedback loop to suppress basal ERK1/2 when oncogenic Ras stimulates the Ras/Raf/MEK1/2/ERK1/2 cascade. ERK1/2 was required to maintain elevated MKP-3, indicative of a negative feedback loop. Accordingly, knockdown of MKP-3, via siRNA, increased ERK1/2 phosphorylation. Second, by using siRNA, we found that MKP-3 helps establish the sensitivity of ERK1/2 to extracellular activators by limiting the duration of ERK1/2 phosphorylation. Third, we found that the regulation of ERK1/2 by MKP-3 is countered by the complex regulation of MKP-3 by ERK1/2. Potent ERK1/2 activators stimulated the loss of MKP-3 within 30 min due to an ERK1/2-dependent decrease in MKP-3 protein stability. MKP-3 levels recovered within 120 min due to ERK1/2-dependent resynthesis. Preventing MKP-3 resynthesis, via siRNA, prolonged ERK1/2 phosphorylation. Altogether, these results suggest that under the pressure of oncogenic Ras expression, MKP-3 reins in ERK1/2 by serving in ERK1/2-dependent negative feedback pathways.
Zeliadt
Nicholette A
NA
Division of Environmental Health Sciences, School of Public Health, University of Minnesota, Mayo Mail Code #807, 420 Delaware Street SE, Minneapolis, MN 55455, USA.
Mauro
Laura J
LJ
Wattenberg
Elizabeth V
EV
D045744:Cell Line, Tumor; D054642:Dual Specificity Phosphatase 6 / Q000502:physiology*; D011905:Genes, ras; D006801:Humans; D019950:Mitogen-Activated Protein Kinase 1 / Q000502:physiology*; D048052:Mitogen-Activated Protein Kinase 3 / Q000502:physiology*; D010766:Phosphorylation
D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3; C517035:DUSP6 protein, human; D054642:Dual Specificity Phosphatase 6
Science. 1999 Nov 12;286(5443):1374-7
10558995
Nat Biotechnol. 2004 Mar;22(3):326-30
14758366
J Biol Chem. 2004 Aug 6;279(32):33085-92
15159408
Toxicol Appl Pharmacol. 2002 Nov 15;185(1):8-17
12460732
Cell Signal. 2004 Jul;16(7):769-79
15115656
EMBO J. 1996 Jul 15;15(14):3621-32
8670865
J Biol Chem. 2004 Oct 1;279(40):41882-91
15269220
Oncogene. 2007 May 14;26(22):3203-13
17496916
Nat Genet. 2005 Jan;37(1):48-55
15608639
J Biol Chem. 1996 Mar 15;271(11):6497-501
8626452
Cancer Res. 2006 Jun 1;66(11):5950-9
16740736
Nature. 1983 May 5-11;303(5912):72-4
6843661
J Biol Chem. 2004 Oct 22;279(43):44731-9
15284227
Nat Rev Cancer. 2003 Jan;3(1):11-22
12509763
J Biol Chem. 1999 Sep 10;274(37):26563-71
10473620
FEBS Lett. 1998 Mar 27;425(2):271-6
9559664
J Biol Chem. 2003 Jan 31;278(5):2903-12
12419823
Nature. 1987 May 28-Jun 3;327(6120):293-7
3587348
J Dermatol Sci. 1998 May;17(1):1-7
9651822
Toxicol Appl Pharmacol. 2003 Nov 1;192(3):212-21
14575638
Mol Cell Biol. 2005 Jan;25(2):854-64
15632084
J Steroid Biochem Mol Biol. 2002 Feb;80(2):239-56
11897507
Science. 1993 Apr 2;260(5104):85-8
8465203
J Cell Sci. 1998 Nov;111 ( Pt 22):3389-99
9788880
J Biol Chem. 1997 Jul 4;272(27):16917-23
9202001
Blood. 2003 Oct 1;102(7):2581-92
12791645
Oncogene. 2007 May 14;26(22):3279-90
17496922
J Biol Chem. 1996 Feb 23;271(8):4319-26
8626780
Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12759-64
14566055
Dev Dyn. 2005 Mar;232(3):695-708
15704110
Endocrinology. 2006 Oct;147(10):4931-40
16840544
Am J Pathol. 2003 Jun;162(6):1807-15
12759238
Cell. 1995 Jan 27;80(2):179-85
7834738
Mol Cell Biol. 2008 Jan;28(1):511-27
17967895
FASEB J. 2000 Jan;14(1):6-16
10627275
Chem Rev. 2001 Aug;101(8):2449-76
11749383
Development. 2004 Jun;131(12):2769-79
15142973
Br J Cancer. 2005 Aug 8;93(3):310-8
16012519
J Biol Chem. 1995 Mar 31;270(13):7197-203
7535768
J Biol Chem. 1999 Feb 12;274(7):4347-53
9933637
J Biol. 2006;5(5):14
16805921
Development. 2007 Jan;134(1):167-76
17164422
J Biol. 2006;5(5):12
16879720
Nat Cell Biol. 2002 Aug;4(8):556-64
12134156
Nat Cell Biol. 2003 Jun;5(6):513-9
12766772
J Biol Chem. 1998 Apr 10;273(15):9323-9
9535927
Biochem J. 2000 Dec 15;352 Pt 3:701-8
11104676